Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953745 · ClinicalTrials.gov registry record · NA
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00953745 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 43 participants.
The verdict
NCT00953745, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known. This study has been designed to test the hypothesis that the primary mechanism of action of aripiprazole (ARP) antidepressant augmentation is through the dopaminergic pathway. Two positron emission tomography (PET) scan procedures and a functional magnetic resonance imaging (fMRI) scan will be used to test this hypothesis.
Interventions
- DRUG Escitalopram
- DRUG Placebo Tablet
- DRUG Placebo Capsule
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953745
The ClinicalTrials.gov registry entry for NCT00953745 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Escitalopram is the first listed.
NCT00953745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00953745 about?
NCT00953745 is a clinical study titled "Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression". Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known. This study has been designed to test the hypothesis that the primary me...
What is the current status of trial NCT00953745?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2009-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00953745?
The interventions under investigation include: Escitalopram (DRUG), Placebo Tablet (DRUG), Placebo Capsule (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00953745?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.